PBR28

Phase 1Small molecule

NNational Institute of Mental Health (NIMH)

PBR28 is one of 104 small molecule programs targeting Cysticercosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

CysticercosisActive, not recruiting

AtherosclerosisActive, not recruiting

Brain InjuryActive, not recruiting

Multiple SclerosisActive, not recruiting

CysticercosisPhase 1

Active, not recruiting

AtherosclerosisPhase 1

Active, not recruiting

Brain InjuryPhase 1/Phase 2

Active, not recruiting

Multiple SclerosisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Betaseron

Bayer

Preclinical

16 2

Kesimpta

Novartis

Preclinical

15 3

Tysabri

Biogen

Preclinical

14 4

Avonex

EMD Serono

Preclinical

22 5

Zinbryta

Roche

Preclinical

2 6

Flomax

Sanofi

Preclinical

1 7

Pred Forte

Myfortic

Novantrone

Circadin

NNeurim Pharmaceuticals Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Neuroinflammation

NCT04274998

Q4 2027

Phase 1/2Recruiting

Multiple Sclerosis

NCT02649985

Clinical

Trials by Indication[1]

Brain Injury1 trial

Translocator Protein and Inflammation After Traumatic Brain Injury

Completed·NNational Institute of Mental Health (NIMH)·Phase 1/2·NCT01547780·52 enrolled

AIN1 trial

PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)

Terminated·NNational Institute of Mental Health (NIMH)·N/A·NCT00459693·40 enrolled

Neuroinflammation1 trial

Neuroinflammation Imaging in AD

Recruiting·UUniversity of Pennsylvania·Phase 1·NCT04274998·20 enrolled

Multiple Sclerosis1 trial

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

Recruiting·—·Phase 1/2·NCT02649985·250 enrolled

Atherosclerosis1 trial

PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis

Completed·NNational Institute of Mental Health (NIMH)·Phase 1·NCT00547976·5 enrolled

1 more indication

Cysticercosis1 trial

PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28

Completed·NNational Institute of Mental Health (NIMH)·Phase 1·NCT00526916·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for PBR28. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PBR28 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PBR28. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Mental Health (NIMH) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNational Institute of Mental Health (NIMH)

PBR28

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Brain Injury1 trial

AIN1 trial

Neuroinflammation1 trial

Multiple Sclerosis1 trial

Atherosclerosis1 trial

Cysticercosis1 trial

References

Drug Info

Quick Facts

Related News